CLONING AND EXPRESSION OF GENETICALLY ENGINEERED SYNTHETIC ANALGESIC PEPTIDE MOLECULES IN YEAST CELLS AND THERAPEUTIC APPLICATION.
DOI:
https://doi.org/10.61841/r3m6da85Keywords:
Analgesic Peptides, Codon Optimization, , Site Directed Mutagenesis,, Over expression, Synthetic Genes,, Yeast CellsAbstract
The healthier and comfortable life style of age old people and as well as handicapped persons are key indicators for success mile stone achievements in health sector. But in spite of latest equipments and gadgets the old age people and other handicapped persons are compromising on dignity of their life and leading a painful worried life with various ailments impacting their social status and conditions especially pain relaed problems like cancer, osteoporosis, spinal injuries artificial transplantation of limbs or organs,. These are all associated with heavy and chronic pain conditions. Severe pain is the most serious phobic condition for any patient who is undergoing surgical treatments. Even though the modern drugs are giving some analgesic effects, but they are showing more side effects and as well as most of the time they are fatal to organ or patients. In order to minimize the gap we would like to find out more suitable and effective natural novel analgesic peptide molecules by employing genetic engineering methods.Synthetic Analgesic peptide genes were prepared by Gene Cloning Methods. Site directed mutagenesis and codon optimization methods were adopted for development of recombinant synthetic genes. Their suitability of expression are verified insilico methods using various computational bioinformatics Tools like Vector 2.0 and Accelrys DS Modeller.The developed synthetic genes were cloned in suitable vectors and Expressed in Yeast Cells. Clones were purified and tested for their effectiveness of analgesic activities on mice models using hot plate assay method and Tail Immersion Methods.Our Synthetic genetically engineered built products were given prominent results when compared with standard analgesic molecules (55-70% effiency) that are available in market.Therefore, the challenge is encountered by these small synthetic recombinant genetically engineered molecules which competed with commercial well known chemical drugs, which have lot of side effects.
Downloads
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
